Javascript must be enabled to continue!
1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
View through CrossRef
DA-1726 showed superior weight loss efficacy compared to Semaglutide (SEMA) in DIO mice. In this following study, a dose-response of DA-1726 was evaluated to determine the maximum efficacy in DIO rats that are known to have good translatability to human studies. The half-life of DA-1726 was longer in rats compared to mice, however the in vitro activity of DA-1726 against rat glucagon receptor was less potent than in the mouse, and plasma protein binding was approximately 10-fold higher in rats. Therefore, we set the effective dose for rats higher than for mice. DA-1726 was injected twice a week for about 4 weeks, a dose-dependent and significant weight loss effect was observed. The minimum effective dose in DIO rats was found to be 250 nmol/kg. Then, the maximum body weight loss effects of DA-1726 (500 and 1000 nmole/kg) and SEMA were compared in the DIO rat. In this study, DA-1726 showed an excellent weight loss effect than SEMA (32.6% for DA-1726 at a high dose vs. 24.0% for SEMA, p<0.05). The low-dose DA-1726 group showed a similar effect compared to SEMA even though they consumed more food. The high-dose DA-1726 group showed similar food intake as SEMA, but led to a higher weight loss effect. After repeated dosing, the high-dose DA-1726 significantly increased the expression of energy metabolism-related genes (Ucp1, Ppargc1a) in white adipose tissues (WAT), supporting increased energy expenditure. So then, in order to confirm whether this increased gene change was a direct effect leading to weight loss or an indirect effect caused by weight loss, we assessed the changes in gene expression after single dosing. DA-1726 (250 and 500 nmol/kg) induced small but significant weight loss 3 days after a single injection (-7.6% and -9.5% vs. control). However, the genes expression (Ucp1, Ppargc1a) in WAT was significantly increased only in the 500 nmol/kg-treated group suggesting a direct effect. Therefore, DA-1726 is expected to elicit excellent weight loss effects in humans with a new mechanism.
Disclosure
Y.Chae: None. T.Kim: None. I.Jung: None. H.Kim: None. M.Kim: Employee; Dong-A ST.
American Diabetes Association
Title: 1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
Description:
DA-1726 showed superior weight loss efficacy compared to Semaglutide (SEMA) in DIO mice.
In this following study, a dose-response of DA-1726 was evaluated to determine the maximum efficacy in DIO rats that are known to have good translatability to human studies.
The half-life of DA-1726 was longer in rats compared to mice, however the in vitro activity of DA-1726 against rat glucagon receptor was less potent than in the mouse, and plasma protein binding was approximately 10-fold higher in rats.
Therefore, we set the effective dose for rats higher than for mice.
DA-1726 was injected twice a week for about 4 weeks, a dose-dependent and significant weight loss effect was observed.
The minimum effective dose in DIO rats was found to be 250 nmol/kg.
Then, the maximum body weight loss effects of DA-1726 (500 and 1000 nmole/kg) and SEMA were compared in the DIO rat.
In this study, DA-1726 showed an excellent weight loss effect than SEMA (32.
6% for DA-1726 at a high dose vs.
24.
0% for SEMA, p<0.
05).
The low-dose DA-1726 group showed a similar effect compared to SEMA even though they consumed more food.
The high-dose DA-1726 group showed similar food intake as SEMA, but led to a higher weight loss effect.
After repeated dosing, the high-dose DA-1726 significantly increased the expression of energy metabolism-related genes (Ucp1, Ppargc1a) in white adipose tissues (WAT), supporting increased energy expenditure.
So then, in order to confirm whether this increased gene change was a direct effect leading to weight loss or an indirect effect caused by weight loss, we assessed the changes in gene expression after single dosing.
DA-1726 (250 and 500 nmol/kg) induced small but significant weight loss 3 days after a single injection (-7.
6% and -9.
5% vs.
control).
However, the genes expression (Ucp1, Ppargc1a) in WAT was significantly increased only in the 500 nmol/kg-treated group suggesting a direct effect.
Therefore, DA-1726 is expected to elicit excellent weight loss effects in humans with a new mechanism.
Disclosure
Y.
Chae: None.
T.
Kim: None.
I.
Jung: None.
H.
Kim: None.
M.
Kim: Employee; Dong-A ST.
Related Results
1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
DA-1726 is a novel oxyntomodulin analogue preparing for phase I clinical trials for obesity. In this study, the pharmacological effect of DA-1726 compared to other competitor pepti...
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
Glucagon regulates metabolic functions through the glucagon receptor (GCGR). Agonists as well as antagonists of GCGR are evaluated as treatments of diabetes and obesity. To underst...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
<b>Background and Purpose:</b> Periodontitis combines persistent inflammation with impaired periodontal regeneration. We investigated whether post-translational modific...
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons
Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons
Abstract
Glucagon-like peptide 1 receptor (GLP1R) agonists like semaglutide drive weight loss through the brain, but insights into their intracel...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
Periodontitis is characterized by persistent inflammation and impaired periodontal regeneration, but the mechanism linking these processes remains unclear. Here, we identified a pa...
2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management
2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management
DA-1726 is being prepared for obesity Phase 1 clinical trials following IND approval. Our study focuses on the pharmacological effects of this novel oxyntomodulin analogue, which h...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED] Prima Weight Loss Dragons Den UK v1
[RETRACTED]Prima Weight Loss Dragons Den UK :-Obesity is a not kidding medical issue brought about by devouring an excessive amount of fat, eating terrible food sources, and practi...

